N/A
Completed N=5,271
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
Source: ClinicalTrials.gov NCT01819935 ↗Enrolled (actual)
5,271
Serious AEs
—
Results posted
Jan 2014
Primary outcomePrimary: Time to 30-day Mortality — 15; 14 days
Summary
The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to 30-day Mortality |
15; 14 | — |
| SECONDARY Time to Therapy Change |
4; 4 | — |
| SECONDARY Time to Discharge From the Hospital |
19.7; 20.3 | — |
| SECONDARY Time to Transfer Out From the Intensive Care Unit (ICU) |
2; 4 | — |
| SECONDARY Time to Intubation |
5; 3 | — |
| SECONDARY Time to 30-day Re-admission |
10; 11 | — |
| SECONDARY Time to 30-day Methicillin-Resistant Staphylococcus Aureus (MRSA) Re-infection |
17; 11 | — |
| SECONDARY Clinical Success |
50.9; 46 | — |
Eligibility Criteria
Inclusion Criteria
- MRSA and pneumonia cases by ICD-9 code identification.
- Diagnosis included during inpatient stay.
- Treatment initiation in hospital.
Exclusion Criteria
- Death of discharge within 3 days of treatment initiation.
- Exposure to other treatments with MRSA activity.
Data sourced from ClinicalTrials.gov (NCT01819935). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.